BioXcel Therapeutics, Inc. (BTAI)

BioXcel Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Oct 8, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	53	19	86	602	569	1,126
Market Cap Growth	124.96%	-78.51%	-85.65%	5.82%	-49.47%	327.27%
Enterprise Value	141	83	96	462	317	895
Last Close Price	2.50	5.98	47.20	343.68	325.28	739.20
PS Ratio	13.24	8.19	62.58	1605.17	-	-
PB Ratio	-	-0.20	-1.53	7.84	2.57	5.45
P/TBV Ratio	-	-	-	7.84	2.57	5.45
EV/Sales Ratio	162.01	36.69	69.82	1233.33	-	-
Debt / Equity Ratio	-1.01	-1.11	-1.79	1.22	0.01	0.01
Asset Turnover	0.02	0.04	0.01	0.00	-	-
Inventory Turnover	1.33	1.61	0.63	-	-	-
Quick Ratio	0.52	1.35	2.40	5.90	13.98	18.00
Current Ratio	0.76	1.68	2.65	6.17	14.21	18.33
Return on Equity (ROE)	-	-	-1766.94%	-111.08%	-49.93%	-70.35%
Return on Assets (ROA)	-68.72%	-72.30%	-74.95%	-44.81%	-29.10%	-40.13%
Return on Capital (ROIC)	-204.90%	-148.97%	-97.39%	-50.73%	-31.02%	-43.59%
Earnings Yield	-103.73%	-321.18%	-207.35%	-27.54%	-18.80%	-7.30%
FCF Yield	-113.54%	-388.15%	-179.52%	-22.51%	-14.52%	-5.92%
Buyback Yield / Dilution	-126.53%	-39.21%	-4.00%	-6.23%	-21.63%	-33.11%

Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q